Project Grant R21AR085266
Award Date
9/20/24
Completion Date
8/31/26
Dollars Obligated
$375K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a Project Grant (CFDA 93.846) totaling $715,957 to Northwestern University to conduct research on the mechanisms underlying interferon-induced T peripheral helper (Tph) cell differentiation in systemic lupus erythematosus (SLE). The research aims to elucidate how high levels of circulating type I interferon contribute to the pathological expansion of Tph cells, which are associated with increased...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), totals $216,113 and is aimed at investigating the mechanism of hematological abnormalities in systemic autoimmunity. The research, to be conducted by New York University School of Medicine, will characterize the impairment of hematopoietic stem cells (HSCs) in a mouse model of systemic lupus...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under CFDA 93.846 Arthritis, Musculoskeletal and Skin Diseases Research provides $405,350 to The Feinstein Institutes for Medical Research to conduct research on the role of lipid droplets in macrophages and their consequences in lupus. The research aims to (1) characterize lipid droplets in macrophage subsets and (2) determine if manipulating the content or quantity of lipid...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $793,093 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the Oklahoma Medical Research Foundation (OMRF) to conduct research on defining the regulatory landscape of systemic lupus erythematosus (SLE) and its comorbidity with cardiovascular disease (CVD). The research aims to identify genetic factors that contribute to both SLE and CVD by studying the impact of SLE-associated genetic...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded The Medical University of South Carolina (MUSC) a $365,420 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to study the role of the SLE causal variant NCF1.PR90H in promoting kidney damage. The 2-year project aims to investigate how this genetic variant impacts the function of the NADPH oxidase complex and contributes to systemic lupus erythematosus...
This Project Grant award of $788,508 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research into the links between cutaneous photosensitivity, systemic autoimmunity, and lymphatic dysfunction in systemic lupus erythematosus (SLE). The research aims to delineate the determinants of Langerhans cell (LC) licensing for lymphatic regulation, identify the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $256,808.00 to the University of Washington to study the molecular mechanisms that cause and perpetuate systemic lupus erythematosus (SLE). The research aims to investigate how dysregulated mRNA splicing in SLE neutrophils can affect their function and generate novel autoantigens. Key objectives include...
This $173,556 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports a five-year research study by Yale University to investigate the role of retroelements in the pathogenesis of systemic lupus erythematosus (SLE), a highly morbid autoimmune disease. The key objectives are to: 1) delineate gene and retroelement expression patterns as well as inflammatory cytokine levels in the blood and skin of SLE...
This $2,685,420 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the commercialization readiness of immune mediator-based blood tests that inform current and future clinical disease activity in patients with systemic lupus erythematosus (SLE). The key products to be developed and validated through this late-stage research project are the Lupus Flare Risk Index (L-FRI)...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $555,774 to the University of Alabama at Birmingham (UAB) to conduct research on the role of the aryl hydrocarbon receptor (AhR) pathway in suppressing the development of T-bet+ B cells in systemic lupus erythematosus (SLE). The key objectives are to determine if IL-4 acts through the AhR pathway to inhibit the...